02.12.2014 • NewsNovartisGilenyaVasant Narasimhan

Novartis’s Gilenya Fails on Primary Progressive MS

In a late-stage study involving 970 people with primary-progressive multiple sclerosis (PPMS), the Novartis drug Gilenya (fingolimod) failed to show any significant advantages over a placebo in a combination of disability measures the Swiss-based pharmaceutical producer said.

Gilenya is already approved in the US and Europe as a treatment for the more common relapsing-remitting form of multiple sclerosis. It currently is being tested in Phase III trials as a treatment for pediatric MS and chronic inflammatory demyelinating polyradiculoneuropathy (CIDP).

There is currently no approved treatment for PPMS, a form of the disease that involves a steady worsening of brain function and affects about 10% of all people diagnosed with multiple sclerosis worldwide, some 2.3 million.

Gilenya had been predicted to be Novartis's best-selling product by 2016, with analysts forecasting $3.2 billion in sales. "We understand this news is very disappointing for those affected by PPMS," Vasant Narasimhan, head of development at Novartis's pharmaceuticals division, said.

"While PPMS is a focus of the MS community, relatively little is known about the disease, so finding effective treatments remains a challenge," he added.

Free Virtual Event

Sustainability in Bioprocessing
Bioprocess Forum

Sustainability in Bioprocessing

Join us to explore hot topics in sustainable bioprocessing like the industrial potential of enzymatic synthesis, innovative biocatalysis techniques, and the use of digital twins in bioprocessing.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.